A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19

The Role of Hydroxychloroquine in the Age of COVID-19: A Periodic Systematic Review and Meta-Analysis

“…Kim et al in their opinion publication for the COVID-19 Global Rheumatology Alliance pointed at the shortage of HCQ following a sudden high demand after Gautret and colleagues' publication on 20 March 2020 (10). They also referred to that HCQ is a crucial treatment choice for patients with systemic lupus erythematosus and rheumatoid arthritis disorders, who get into trouble in finding HCQ in this critical time (20). Authors recommend that scientific communities have to be very cautious and do not rush in decision when there is no ample evidence for the subject, especially in such critical situations, which can lead to irreparable consequences.…”

Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist

“…In a small non-randomised pilot trial including 26 people with covid-19 initially treated with HCQ (and azithromycin (AZM) in an additional subset), nasopharyngeal viral clearance at day 6 of treatment was reported in 57% of the 14 patients retained in the analysis who received HCQ monotherapy versus 13% of controls. 17 However, concerns about the study design and data analysis have been previously discussed, 18 and a potential signal toward increased harm in patients treated with HCQ cannot be dismissed outright. Since then, another preprint by Gautret et al described a selected cohort of 80 patients with covid-19.…”

Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks

“…42 For example, based on a small clinical study, 43 the combination of hydroxychloroquine (a small molecule traditionally used to treat malaria and lupus) and azithromycin (a macrolide antibiotic with anti-inflammatory properties) has been suggested as a means to reduce SARS-CoV-2 viral load, although these results are controversial. 44 Poly(lactide) and poly(lactide-co-glycolide) (PLGA) microparticles can deliver azithromycin for up to 60 days with zero-order release kinetics. 45 There are also formulations using fumaryl diketopiperazine microparticles to deliver azithromycin via intratracheal insufflation directly to the lungs, resulting in higher local concentrations in a murine pneumonia model compared to oral and intravenous routes of delivery.…”